Oxford-AstraZeneca coronavirus vaccine developers confirm that its vaccine will help people from contracting the infection, giving a promising yet vague solution to one of the pandemic's great remaining concerns.
Vaccines have proven that they could successfully decrease the number of patients who develop complications or undergo severe disease. However, even less is understood whether either of the vaccines available will avoid asymptomatic infections that can move from one person to another, thus reducing the need for social distancing and facilitating a return to a more regular life.
Doses of the Oxford University/AstraZeneca Covid-19 vaccine arrive at the Princess Royal Hospital in Haywards Heath on January 02, 2021 in West Sussex, United Kingdom.
Viral Propagation Elimination
According to the New York Times, the research is the first to record such an influence on the novel coronavirus, and it appears that the AstraZeneca shots are the first to have that effect.
Each week, the experts swabbed participants to watch for signs of the virus to test the influence on disseminating the virus. If they find no virus, even if the individual has been contaminated with COVID-19, it indicates that they will not transmit it to anyone.
Based on the study, the team observed that the positive swabs among the participants who were injected with the AstraZeneca shots were decreased by 67 percent.
The research reported that the injection of the vaccine would decrease virus spread by about two-thirds.
ALSO READ: AstraZeneca Says Its COVID-19 Vaccine Has A 'Winning Formula;' Will It Work On New COVID-19 Strain?
76 Percent Successful
Moreover, the study also showed that a single injection of the vaccine is 76 percent successful against COVID-19, with data obtained three months after the vaccine's first shot was taken by the patients. This would not involve the first three weeks needed to take place to include the requisite defense for the shot.
The outcome has offered help not only to Britain but also to other countries who have made agreements with AstraZeneca and Oxford to prioritize providing the first dose to as many individuals as possible even though the second dose is later than originally expected.
However, the same cannot be said about the Pfizer and Moderna vaccines, the two vaccines approved for use in the United States. It has been released by AstraZeneca and Oxford researchers on a pre-print website for those who wish to verify the results of the analysis, indicating it has not yet been peer-reviewed.
Further analysis also shows that the #OxfordVaccine may have a substantial effect on coronavirus transmission, with 67% reduction in positive PCR swabs among those who have been vaccinated: https://t.co/7aZAWgFqQH
— University of Oxford (@UniofOxford) February 2, 2021
More Needed Data
Stephen Evans, a pharmacoepidemiology professor at the London School of Hygiene and Tropical Medicine, said the paper's supplementary knowledge was beneficial. Still, there remained some "inevitable uncertainty" regarding the precise values of efficacy.
"The data provide some evidence to suggest that the eventual protection from two doses of this vaccine are not worsened by having a longer than 28 or 42 day period between doses and tend to confirm what had been shown before, that if anything the eventual efficacy was better," he said per CNN report.
"The data also do not provide any evidence that efficacy wanes after the first dose," he added.
Similar evidence on the delay of the second dose of the Pfizer/BioNTech vaccine to 12 weeks after the first dose is not yet available, Dr. Gillies O'Bryan-Tear, former Chair of Strategy and Marketing at the Faculty of Pharmaceutical Medicine, said in comments to the SMC. He said several commentators accept that this vaccination is likely to be the same as the other two doses of the vaccine.
The authors warned that the experiments were not originally meant to test effectiveness through dosage cycles. The data emerged because of the logistics of conducting large-scale pandemic clinical trials.
Last month, AstraZeneca reported that it had finished its participation in its Phase 3 study in the United States, which would act as "the primary basis" for the firm's potential submission to the US Food and Drug Administration.
In various countries, such as the United Kingdom and India, the vaccination has already been authorized. Still, permission will not be given in the US until late March at the earliest.
ALSO READ: Volunteer for Pfizer's Experimental COVID-19 Vaccine Shares Side Effects from Trial
Check out more news and information on COVID-19 on Science Times.
